Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy

Sorafenib is the standard first-line drug for the treatment of advanced hepatocellular carcinoma (HCC), however, its therapeutic efficacy is not satisfactory due to primary or secondary resistance of HCC cells. In the present study, we identified Metaxin 1 (MTX1) as a new regulator of sorafenib resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Yu, Shijun, Hu, Qingqing, Hai, Yanan, Li, Yandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375235/
https://www.ncbi.nlm.nih.gov/pubmed/34421355
http://dx.doi.org/10.7150/ijbs.62393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375235/
https://www.ncbi.nlm.nih.gov/pubmed/34421355
http://dx.doi.org/10.7150/ijbs.62393

Ejemplares similares